2 quality ASX shares that have been sold-off

Some of the high-quality ASX shares have been sold off.

Key points
  • These two quality ASX shares have seen sell-offs this year
  • The MOAT ETF is a portfolio of businesses that are expected to keep hold of their strong competitive advantages for many years ahead
  • Pro Medicus is a high-quality ASX healthcare share which is growth globally, with high profit margins

There has been a lot of volatility this week, and this year. Quality ASX shares, and the less-so-quality ones, have been sold down.

Times of market volatility can mean that the quality investments get beaten up, sometimes unfairly.

Here are two ASX shares that have seen sizeable declines in recent times:

ASX shares profit upgrade chart showing growth

Image source: Getty Images

VanEck Morningstar Wide Moat ETF (ASX: MOAT)

This is an exchange-traded fund (ETF) which specialises in offering investors exposure to businesses with strong economic moats.

Another way of describing an economic moat is calling it a competitive advantage. A competitive advantage can come from a number of different things including a brand, the scale of a business, intellectual property, cost advantages and so on.

For a stock to be considered for this ETF's portfolio, it must (with near certainty) be able to generate outsized profits for the next decade and more likely than not for the decade after that.

If a company ticks the box as having a wide economic moat, it will only get added to the ETF if it is deemed to be trading at good value compared to the estimate of fair value by analysts at Morningstar.

At the latest disclosure, the companies that have a weighting of at least 2.9% are: Cheniere Energy, Philip Morris, Bristol-Myers Squibb, Lockheed Martin, Wells Fargo, Corteva, Altria and Berkshire Hathaway.

It has an annual management fee of 0.49%. Over the last five years to 31 January 2022, it has produced a net return per annum of around 1% more than the S&P, with a net return of 18.9% per annum.

Pro Medicus Limited (ASX: PME)

Pro Medicus is a quality medical imaging IT ASX share. It offers Visage Imaging, which is a global platform of enterprise imaging solutions.

Since the start of the year, the Pro Medicus share price has fallen by 27.2%.

It wasn't long ago that the business reported a lot of growth in its FY22 half-year result as it benefits from the large, long-term contracts it has won and the high profit margins it has.

HY22 revenue rose by 40.3% and net profit jumped 52.7% to $20.7 million. This helped fund a rise of the interim dividend by 42.9% to 10 cents per share. Its earnings before interest and tax (EBIT) margin was close to 65%.

Pro Medicus said that it is making significant progress with all key implementations being on or ahead of schedule.

The ASX share also revealed that its pipeline remains strong, with a good spread of opportunities in different markets. Many of these opportunities are cloud-based, a trend which is gathering momentum and many are interested in more than one Visage solution.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended VanEck Vectors Morningstar Wide Moat ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

Man looking happy and excited as he looks at his mobile phone.
Growth Shares

Could this ASX 200 share turn $10,000 into $20,000 by 2030?

The company already has an impressive global presence, but I think there's still plenty of room to grow.

Read more »

Two shop workers smiling and looking at a laptop surrounded by plants.
Growth Shares

The ASX's next great growth stock? I've narrowed my shortlist to two

These companies have already made impressive progress, but I think there's still a lot more they could achieve.

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Growth Shares

2 ASX shares highly recommended to buy: Experts

Multiple brokers are excited about these ideas.

Read more »

A couple sits on the bed in their hotel room wearing white robes, with both having seen bad news on their phones.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is delivering significant financial growth.

Read more »

Two work colleagues looking at a laptop and discussing something.
Growth Shares

If I could own just one ASX share for the next decade, these 5 would make my shortlist

Let's see which shares made the cut.

Read more »

Watering can pouring water on increasing piles of coins with green plants on them and a piggy bank and coins on the table.
Growth Shares

My $5k bullish growth play: 3 exciting ASX stocks I just bought for retirement

I’m excited by what these stocks could achieve in the future.

Read more »

Hourglass in a hand with white lines and dollar signs.
Growth Shares

2 top ASX shares to buy and hold for the next decade

I think these businesses have a very exciting future.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Growth Shares

Where I'd invest $10,000 in ASX growth shares

These shares have strong growth outlooks. Let's get to know them better.

Read more »